Beyond serving as a scaffold for the organization of cells into tissues, the extracellular matrix (ECM) is also a multifunctional regulator of cellular behaviour. ECM proteins can modulate the activity or bioavailability of extracellular signalling molecules such as growth factors, cytokines, chemokines and extracellular enzymes, or they can directly bind to and signal through cell-surface receptors to regulate cellular functions. A subset of ECM proteins, known as matricellular proteins, are dynamically expressed and serve primarily regulatory rather than structural roles 1, 2 . Among known matricellular proteins are members of the CCN protein family, a group of highly conserved secreted proteins that have been identified by differential expression screening [2] [3] [4] . The synthesis of these proteins is regulated by mitogenic growth factors or oncogenic transformation. The acronym 'CCN' is derived from the first three members of the protein family described, namely cysteine-rich angiogenic inducer 61 (CYR61; also known as CCN1), connective tissue growth factor (CTGF; also known as CCN2) and nephroblastoma overexpressed (NOV; also known as CCN3). Together with a set of three WNT-inducible signalling pathway proteins -WISP1 (also known as CCN4), WISP2 (also known as CCN5) and WISP3 (also known as CCN6) -they comprise a family of six homologous cysteine-rich proteins in mammals that have been renamed CCN1-CCN6 by international consensus 5 . All CCN proteins have a similar modular structure, which consists of an amino-terminal secretory peptide followed by four conserved domains with sequence homologies to insulin-like growth factor-binding proteins, the von Willebrand factor C (VWC) domain, thrombospondin type 1 repeat (TSR) and a carboxy-terminal domain that contains a cysteine-knot motif (BOX 1). A nonconserved, protease-sensitive central hinge region bisects the proteins into two halves that bind to distinct cellsurface receptors. The expression of CCN proteins is exquisitely regulated on transcriptional, post-transcriptional and translational levels in response to changes in environmental stimuli, including those encountered during tissue repair (BOX 1; FIG. 1) .
. Among known matricellular proteins are members of the CCN protein family, a group of highly conserved secreted proteins that have been identified by differential expression screening [2] [3] [4] . The synthesis of these proteins is regulated by mitogenic growth factors or oncogenic transformation. The acronym 'CCN' is derived from the first three members of the protein family described, namely cysteine-rich angiogenic inducer 61 (CYR61; also known as CCN1), connective tissue growth factor (CTGF; also known as CCN2) and nephroblastoma overexpressed (NOV; also known as CCN3). Together with a set of three WNT-inducible signalling pathway proteins -WISP1 (also known as CCN4), WISP2 (also known as CCN5) and WISP3 (also known as CCN6) -they comprise a family of six homologous cysteine-rich proteins in mammals that have been renamed CCN1-CCN6 by international consensus 5 . All CCN proteins have a similar modular structure, which consists of an amino-terminal secretory peptide followed by four conserved domains with sequence homologies to insulin-like growth factor-binding proteins, the von Willebrand factor C (VWC) domain, thrombospondin type 1 repeat (TSR) and a carboxy-terminal domain that contains a cysteine-knot motif
. A nonconserved, protease-sensitive central hinge region bisects the proteins into two halves that bind to distinct cellsurface receptors. The expression of CCN proteins is exquisitely regulated on transcriptional, post-transcriptional and translational levels in response to changes in environmental stimuli, including those encountered during tissue repair At the cellular level, CCN proteins regulate cell adhesion, migration, proliferation, differentiation, apoptosis, survival, senescence and gene expression. By modulating one or more aspects of these cellular functions in a cellspecific manner, CCN proteins coordinate complex biological processes, including cardiovascular and skeletal development during embryogenesis, as well as inflammation, wound healing and tissue repair in adulthood. Aberrant expression of CCN proteins is associated with a remarkable range of seemingly unrelated diseases. A useful albeit simplistic framework with which to rationalize the roles of CCN proteins in this array of diseases is that many pathological conditions arise when inflammation or tissue injury becomes chronic, and in this process CCN proteins are concomitantly deregulated.
Studies in animal models and in patients have confirmed that CCN proteins are involved in many diseases related to inflammation and tissue repair, including arthritis, atherosclerosis, restenosis after vascular injury, Nature Reviews | Drug Discovery 6 . However, the therapeutic potential of other CCN proteins has yet to be evaluated in a clinical setting. In this Review, we discuss recent insights into the regulation and function of CCN proteins in various biological processes, summarize the evidence for their participation in disease pathologies, explore their potential as diagnostic markers and therapeutic targets, and discuss various targeting strategies as applied to these proteins.
Functions and mechanisms of action
As members of the CCN protein family serve both distinct and overlapping biological roles, these highly conserved proteins bind many of the same receptors and function through similar mechanisms to regulate a common set of biological processes. However, the specific biological responses to some of the CCN proteins may be similar in some cell types but different in others, and at times diametrically opposed. Nevertheless, some generalizations can be made about how CCN proteins function. First, many activities of CCN proteins are mediated through their direct binding to integrin receptors on the cell surface, with the participation of one or more co-receptors in some contexts. The convergence of signals initiated from multiple receptors in some cases leads to unique biological responses that are not achieved with a single receptor, and the requirement of multiple receptors for certain functions of CCN proteins contributes to target cell specificity. Second, CCN proteins can regulate the expression of biologically active molecules such as growth factors, cytokines and matrix metalloproteinases (MMPs), and physically interact with some of these molecules to modulate their bioavailability and activity (FIG. 2) . In addition, CCN proteins can interact with and be tethered to other ECM proteins -including decorin, fibronectin, vitronectin and perlecan -potentially functioning as a local scaffold that coordinates the interaction of specific biologically active molecules or ECM proteins with the target cell (FIG. 2) . Third, CCN proteins can profoundly alter the biological activities of cytokines, and possibly growth factors, through signalling crosstalk (FIG. 3) . Through these and other mechanisms
, CCN proteins can integrate and modulate multiple signalling pathways to elicit cell-specific responses.
Cell-surface receptors. Many activities of CCN proteins are mediated through their direct binding to integrin receptors, with the involvement of co-receptors in some contexts (TABLE 1) . At least eight integrins have been shown to bind CCN proteins 2 . As distinct integrins are differentially expressed in various cell types and may mediate disparate activities, CCN proteins can achieve remarkable
Box 1 | The CCN family of matricellular proteins
The CCN matricellular proteins (except for WNT-inducible signalling pathway protein 2 (WISP2; also known as CCN5)) are composed of an amino-terminal secretory peptide and four conserved modular domains: the insulin-like growth factor binding protein (IGFBP) domain, the von Willebrand factor C (VWC) domain, the thrombospondin type 1 repeat (TSR) domain and the carboxy-terminal domain. Each of these domains is encoded by a separate exon. A non-conserved central hinge region divides the protein into two halves with different binding capabilities for extracellular proteins and cell-surface receptors (FIG. 2) . The locations of identified binding sites for integrin receptors and heparan sulphate proteoglycans (HSPGs) are indicated in the schematic diagram 2 . With the exception of CCN5 and CCN6 (also known as WISP3), CCN proteins contain 38 conserved cysteine residues located throughout the polypeptide; CCN5 lacks the precise C-terminal domain but otherwise contains all conserved cysteine residues in the remaining three domains, whereas in CCN6 four cysteine residues in the VWC domain are not conserved.
The genes encoding proteins of the CCN protein family are exquisitely sensitive to regulation by mitogenic signals and a range of environmental perturbations, including exposure to growth factors, inflammatory cytokines, steroid hormones, oxygen deprivation, ultraviolet radiation and mechanical forces (FIG. 1) . During embryonic development, CCN proteins are broadly expressed in many organs and tissues, especially in endothelial cells throughout the embryo and in the developing cardiovascular, skeletal, renal and neuronal systems 32, 177 . During adulthood, expression of CCN proteins is downregulated in many tissues but is upregulated at sites of inflammation, wound healing and tissue repair 2, 36 . Identified as immediate-early genes, the genes encoding cysteine-rich angiogenic inducer 61 (CYR61; also known as CCN1) and connective tissue growth factor (CTGF; also known as CCN2) are expressed at a very low level in quiescent fibroblasts but are transcriptionally activated -without requiring de novo protein synthesiswithin minutes of stimulation by mitogenic growth factors such as platelet-derived growth factor, fibroblast growth factor 2 and transforming growth factor-β1. Analysis of the Ccn1 and Ccn2 promoters has revealed that crucial regulatory elements and transcription factors govern their expression 2, 3 , and the essential promoter for apposite regulation of Ccn1 in transgenic mice has been identified 37 . CCN1 and CCN2 are targets of the transcriptional co-activators Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), which interact with the TEAD family of transcription factors to regulate the expression of genes related to cell proliferation and survival 100 and in response to mechanotransduction 178 (FIG. 2) . By contrast, the nephroblastoma overexpressed gene (NOV; also known as CCN3) and CCN5 are downregulated by mitogenic signals and upregulated under conditions of growth arrest in several cell types 61, 113 . In addition, genes that encode CCN proteins are downregulated by specific microRNAs in various cell types; for example, CCN2 is regulated by miR-133 and miR-30 in cardiomyocytes and miR-18a in chondrocytes 179, 180 , and downregulation of CCN1 by miR-155 may contribute to pre-eclampsia 174 . The presence of internal ribosome entry sites facilitates the preferential translation of the CCN1 mRNA under conditions of cellular stress -for example, after viral infections 181, 182 . Structural variants or isoforms of CCN proteins, some of which have been detected in biological fluids and may have different activities, can be generated by differential splicing 183, 184 , proteolysis 35, 185 and post-translational modifications 186 . Alternative splicing typically results in the production of truncated proteins or proteins with either the VWC or TSR domains deleted. These structural variants have the potential to substantially expand the functional complexity of CCN proteins, although it is currently unknown how they are regulated and how they affect the biological functions of CCN proteins in vivo. Although CCN proteins are secreted proteins with N-terminal signal peptides, they may be endocytosed after binding to receptors. Several CCN proteins have been detected in the nucleus and, although their nuclear function is unknown, studies have suggested the intriguing possibility that CCN1 and CCN5 might regulate transcription 187, 188 .
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Matrix metalloproteinases
Members of a family of >20 zinc-dependent endopeptidases that are involved in the degradation of extracellular matrix proteins, cleavage of cell-surface receptors, release of apoptotic ligands, and activation of chemokines and cytokines.
Integrins
Members of a family of heterodimeric cell-surface signalling receptors that mediate cell-cell and cellmatrix interactions; they are composed of 18 α-subunits and 8 β-subunits, which constitute 24 known integrin heterodimers in mammals.
Immediate-early genes
Genes that are transcriptionally activated with rapid kinetics, without requiring de novo protein synthesis, by a range of stimuli including viral infection or various extracellular signals.
Low-density lipoprotein receptor-related protein
Members of this family of proteins are cell-surface receptors that bind a broad spectrum of ligands, facilitating endocytosis and the signalling of associated receptors.
functional versatility through their interactions with different integrins in a cell-and context-specific manner. Although CCN proteins do not contain the canonical RGD sequence that binds to several integrins, they interact with integrins through their non-canonical binding sites, many of which have been identified
. Sitedirected mutations in these binding sites abolish the specific activities for which the cognate integrins are responsible, both in vitro and in vivo 7, 8 , providing compelling evidence for the role of these integrins in mediating the functions of CCN proteins.
At least two types of co-receptors have been identified for CCN proteins. The first of these are cell-surface heparan sulphate proteoglycans (HSPGs), of which syndecan 4 has been identified as a crucial co-receptor for the functions of CCN proteins 7, 9 . Low-density lipoprotein receptor-related proteins, which are endocytic receptors that cooperate with many growth factor receptors and integrins to modulate cellular responses 10 , are the second class of co-receptor to interact with CCN proteins 11 . CCN2 can interact with neurotrophic tyrosine kinase receptor type 1 (NTRK1; also known as TRKA) in human mesangial cells to enhance transforming growth factor-β (TGFβ) signalling 12 , and in glioma cells to activate nuclear factor-κB (NF-κB) 13 . CCN2 binds to TRKA in a complex with β1 integrins, indicating that TRKA also functions as a co-receptor with integrins 13 . In addition, CCN3 can bind to Notch and suppress myoblast and osteoblast differentiation 14, 15 ; whether integrins are involved in these signalling events is unknown.
Cell adhesion, migration and proliferation. As celladhesive proteins of the ECM, CCN proteins support cell adhesion and promote cell spreading in many cell types (TABLE 1) . The process of cell adhesion may also lead to other cellular responses including cell migration, proliferation and altered gene expression. The adhesion of human skin fibroblasts to CCN1 and CCN2 is mediated through α6β1 integrins and HSPGs, and results in cell-adhesive signalling events including the rapid formation of α6β1 integrin-containing focal adhesion complexes, actin cytoskeleton reorganization, formation of filopodia and lamellipodia, as well as the activation of focal adhesion kinase, paxillin and the small GTPase RAC 16 . The effects of CCN proteins on cell proliferation and migration are cell-specific. In fibroblasts Several extracellular and environmental stimuli rapidly induce the expression of genes encoding CCN proteins; this occurs through the activation of various transcription factors, usually without requiring de novo protein synthesis. These stimuli include: platelet-derived growth factor (PDGF), fibroblast growth factor 2 (FGF2), transforming growth factor-β1 (TGFβ1), interleukin-1β (IL-1β), tumour necrosis factor (TNF), angiotensin II (AT2) 2, 3 , agonists of G protein-coupled receptors (GPCRs) 189 (such as thrombin, prostaglandin (PG), endothelin 1 (ET1) and sphingosine-1-phosphate (S1P)), as well as hormones (such as oestrogen and vitamin D) that bind to steroid hormone receptors (SHRs). Other stimuli include hypoxia, ultraviolet (UV) radiation and mechanical stretch 37, 129 . The locations of the binding sites of various transcription factors vary for each gene encoding CCN proteins. AGTR1, angiotensin II receptor type 1; AP1, activator protein 1; CREB, cyclic AMP-responsive element binding protein; EGR1, early growth response protein 1; HIF1α, hypoxia-inducible factor 1α; IL-1βR, IL-1β receptor; NF-κB, nuclear factor-κB; p38, p38 mitogen-activated protein kinase; RTK, receptor tyrosine kinase; SP1, specificity protein 1; SRF, serum response factor; TAZ, transcriptional co-activator with PDZ-binding motif; TGFβ1R, TGFβ1 receptor; TNFR, TNF receptor; YAP, Yes-associated protein. *The 'CCN' acronym is derived from the first three members of the CCN protein family: cysteine-rich angiogenic inducer 61 (CY61; also known as CCN1), connective tissue growth factor (CTGF; also known as CCN2) and nephroblastoma overexpressed (NOV; also known as CCN3). CCN1, CCN2 and CCN3 have no intrinsic ability to induce mitogenesis on their own but they can enhance DNA synthesis that has been induced by other mitogenic growth factors by acting through αVβ3 integrin 2 . Although CCN2 is capable of promoting DNA synthesis in chondrocytes and osteoblasts 17, 18 , it also induces a G1 cell cycle arrest in mesangial cells 19 . CCN1, CCN2 and CCN3 stimulate cell migration or chemotaxis in fibroblasts and endothelial cells, and promote the invasiveness of certain cancer cells 2 . For example, CCN3 promotes the migration and invasion of Ewing's sarcoma cells but inhibits their proliferation 20 . CCN1 and CCN2 enhance vascular smooth muscle cell proliferation and migration 21, 22 , whereas CCN3 and CCN5 inhibit these processes 23, 24 .
Cell survival, apoptosis and cellular senescence. Cell adhesion to ECM proteins promotes cell survival, whereas detachment from the ECM induces cell death by anoikis in many cell types. Although adhesion of endothelial cells to CCN1, CCN2 or CCN3 through αVβ3 integrin supports cell survival 2 , these CCN proteins can also promote apoptosis as cell adhesion substrates in fibroblasts by interacting with α6β1 integrin 9 . The apoptosis-promoting activity may be most relevant in the context of inflammation as CCN1, CCN2 and CCN3 all have the unusual ability to enable the inflammatory cytokine tumour necrosis factor (TNF) to induce apoptosis without inhibiting NF-κB signalling or de novo protein synthesis -conditions required for TNF cytotoxicity in normal cells in vitro 25 (FIG. 3) . These CCN proteins also facilitate the apoptotic activity of lymphotoxin, and enhance the apoptotic activity of other TNF family cytokines such as the FAS ligand and TNF-related apoptosis-inducing ligand 26, 27 . Knock-in mice expressing an apoptosis-defective Ccn1 allele are substantially resistant to TNF-or FAS-mediated hepatic apoptosis in vivo, indicating that CCN1 is a physiological regulator of TNF-and FAS ligand-mediated cytotoxicity 7, 26 . By contrast, CCN4 inhibits TNF-induced cell death in cardiomyocytes 28 , which suggests that the interplay between various CCN proteins and the TNF family of cytokines may profoundly affect the biological outcome during inflammatory responses.
A recent unexpected finding is that CCN1 can induce cellular senescence in fibroblasts by acting as a cell adhesion molecule 8 . By binding to α6β1 integrin and cellsurface HSPGs, CCN1 activates the RAC1-dependent NADPH oxidase 1 to induce a robust and sustained level of reactive oxygen species production, leading to activation of the cellular tumour antigen p53 and the retinoblastoma-associated protein pRb, which results in senescence (FIG. 3) . An important feature of senescent cells is the expression of the senescence-associated secretory phenotype, which is characterized by the increased expression of ECM-degrading enzymes such as MMPs, inflammatory cytokines and chemokines, and downregulation of ECM components such as collagen, thus imposing a matrix-degrading phenotype 29 . Consequently, CCN1-induced myofibroblast senescence functions as a mechanism for limiting fibrosis during wound healing, as discussed below 30 . Angiogenesis, chondrogenesis and osteogenesis. CCN1, CCN2 and CCN3 are potent angiogenic inducers, functioning through direct binding to αVβ3 integrin in endothelial cells to promote proliferation and induce 190 , perlecan 191 , vitronectin 192 and decorin 168 ), and growth factors (including vascular endothelial growth factor (VEGF) 34 , fibroblast growth factor 2 (FGF2) 193 , transforming growth factor-β (TGFβ) 39 and bone morphogenetic proteins (BMPs) 39 ), as well as the gap junction protein connexin43 (REFS 194, 195) . The specific modular domains mediating the interactions, where elucidated, are indicated. Although fibronectin and perlecan are known to bind to the carboxy-terminal domain, it is not clear whether decorin and vitronectin also bind to this domain. CCN proteins also bind to and signal through several cell-surface receptors including several integrins 2, 37 , which function in concert with heparan sulphate proteoglycans (HSPGs) or low-density lipoprotein receptor-related proteins (LRPs) as co-receptors in some contexts. Connective tissue growth factor (CTGF; also known as CCN2) also binds to neurotrophic tyrosine kinase receptor type 1 (TRKA) in a complex with β1 integrins 13 , both of which act as co-receptors in some contexts, and nephroblastoma overexpressed (NOV; also known as CCN3) can bind to Notch 14 . CCN proteins can modulate WNT signalling, in part by binding to the WNT co-receptor LRP6 (REF. 11 ). The modular domains of CCN proteins may interact in a combinatorial manner to induce unique activities and functions 4 . For example, synergism of cysteine-rich angiogenic inducer 61 (CYR61; also known as CCN1) with tumour necrosis factor requires its binding to both αVβ5 and α6β1 integrins through the von Willebrand factor C (VWC) and C-terminal domains, respectively, to induce signals from both integrins that converge within the cell 7 ; activation of either integrin alone is insufficient. IGFBP, insulin-like growth factor-binding protein; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor-κB; p53, cellular tumour antigen p53; ROS, reactive oxygen species; TSR, thrombospondin type 1 repeat. 31, 32 . They can also regulate the expression 33 and activities of other angiogenic factors such as vascular endothelial growth factor A and vascular endothelial growth factor C 34, 35 . Through their angiogenic activities, these CCN proteins may be involved in embryonic development, inflammatory diseases and tumorigenesis 32, 36 . Both CCN1 and CCN2 promote the differentiation of chondrocytes and osteoblasts 37, 38 . CCN proteins can interact with members of the bone morphogenetic protein (BMP) and TGFβ family, most probably through the chordin-like homology sequence found in the VWC domain, and modulate the binding affinity of BMPs and TGFβ for their respective receptors 39 . CCN2 and CCN3 can bind BMP2 and inhibit its functions in promoting chondrogenic and osteogenic differentiation 15, 40 , respectively, whereas CCN4 can bind BMP2 and enhances its function in osteogenesis 41 . CCN2 regulates WNT signalling by interacting with the WNT receptor complex through direct binding to the WNT co-receptor lowdensity lipoprotein receptor-related protein 6 (REF. 11). CCN1 inhibits osteoclastogenesis 42 , whereas CCN3 stimulates it through a process that may involve calcium flux 43 . In transgenic mice, overexpression of CCN2 or CCN3 in osteoblasts antagonizes both BMP and WNT signalling, and results in osteopaenia 44, 45 . 36 . CCN1 and CCN2 are induced by inflammatory cytokines, or following viral or bacterial infection, and CCN proteins in turn regulate the activity and expression of cytokines and chemokines. Examples include the ability of CCN proteins to substantially alter the cytotoxicity of the TNF family of cytokines, both in vitro and in vivo 7, 26 , as well as the ability of CCN1 to reprogramme macrophages towards M1 polarization and activate the expression of pro-inflammatory cytokines 46 . CCN1 also regulates immune cell infiltration in vivo in an experimental model of autoimmune myocarditis 47 . CCN3 inhibits NF-κB activation in endothelial cells, suggesting that it may regulate endothelial inflammation 48 . Furthermore, CCN proteins are involved in the pathobiology of many inflammatory diseases, as discussed below.
Inflammation. Accumulating evidence indicates that CCN proteins modulate inflammatory responses
Stem cell differentiation and self-renewal.
A recent study has shown that CCN2 activity is sufficient to drive the differentiation of human bone marrow mesenchymal stem cells into α-smooth muscle actin (αSMA)-negative fibroblasts, which are primed for differentiation into αSMA-positive myofibroblasts when they are subsequently treated with TGFβ1 (REF. 49 ). Both CCN1 and CCN2 are targets of the canonical WNT-β-catenin signalling pathway in mesenchymal stem cells, and they regulate the differentiation of these cells into osteoblasts 50, 51 . CCN3 is essential for the self-renewal of CD34 + haematopoietic stem cells from umbilical cord blood, highlighting its potential utility for promoting stem cell engraftment 52 . Consistent with a function in stem cell self-renewal, CCN3 inhibits both myogenic and osteoblastic differentiation of mesenchymal stem cells 53 . also known as CCN1) to α6β1 integrin and heparan sulphate proteoglycans (HSPGs) -for example, syndecan 4 -through the carboxy-terminal domain triggers the activation of RAC1 and NADPH oxidase 1, which leads to substantially more robust and sustained levels of reactive oxygen species (ROS) than via cell adhesion to other extracellular matrix proteins. The sustained levels of ROS induce a DNA damage response as well as the activation of cellular tumour antigen p53, and trigger the activation of extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK), which in turn induces cyclin-dependent kinase inhibitor 2A (CDKN2A) and activates the retinoblastoma-associated protein pRb 8 . Activated p53 and pRb contribute to the induction of cellular senescence. If αVβ5 integrin is also engaged by the von Willebrand factor C (VWC) domain of CCN1, RAC1-dependent ROS accumulation includes contribution from arachidonate 5-lipoxygenase (ALOX5) and the mitochondria 7 ; neutral sphingomyelinase (nSMase) also contributes to CCN1-induced ROS production 26 . CCN1-induced ROS production counteracts the effect of nuclear factor-κB (NF-κB), which is strongly activated by tumour necrosis factor (TNF) and induces the expression of antioxidant proteins. The high level of ROS inhibits cysteine phosphatases that can inactivate MAPKs such as JUN N-terminal kinase (JNK), ERK and p38 MAPK, leading to a hyperactivation of these kinases 196 . Activated JNK targets the proteasomal degradation of cellular FLICE-like inhibitory protein (FLIP) 197 , an inhibitor of caspase activation, which enables the activation of caspase 8 and caspase 10 by TNF to induce apoptosis without blocking de novo protein synthesis or NF-κB signalling 7 . In addition to CCN1, connective tissue growth factor (CTGF; also known as CCN2) and nephroblastoma overexpressed (NOV; also known as CCN3) synergize with TNF to induce apoptosis, presumably through a similar mechanism 25 . In the presence of the FAS ligand (FASL), which can trigger apoptosis on its own, CCN1-or CCN2-induced ROS production leads to the hyperactivation of p38 MAPK, which enhances cytochrome c release from the mitochondria and thereby increases apoptosis 26 . IGFBP, insulin-like growth factor-binding protein; TNFR1, TNF receptor 1; TSR, thrombospondin type 1 repeat.
Cellular senescence
A state of irreversible cell cycle arrest induced by various forms of cellular stresses including DNA damage, oncogene activation, oxidative stress, chromatin disruption and telomere erosion.
Senescence-associated secretory phenotype
A phenotype that is one of the characteristics of senescent cells and includes increased secretion of inflammatory cytokines and matrix-degrading enzymes, as well as downregulation of extracellular matrix proteins such as collagen.
Chondrocytes
Connective tissue cells that produce the cartilaginous matrix, including type II collagen and proteoglycans, and reside within the lacuna of the cartilage matrix.
Osteoblasts
Mononucleate cells that are responsible for bone formation. They produce osteoid, which is composed mainly of type I collagen, and are responsible for mineralization of the osteoid matrix.
CCN proteins in embryonic development
Targeted disruptions of genes encoding CCN proteins in mice have been accomplished (with the exception of Ccn4), and phenotypes of the knockout mice are listed in TABLE 2. Although the phenotypes of each knockout mouse are distinct, skeletal and vascular defects are among the most commonly observed phenotypes. Given the importance of several CCN proteins in ovulation, placentation and development, the potential risks of targeting their expression or function in pregnant women or in women who are intending to get pregnant should be carefully evaluated. Ccn1-null mice are embryonic lethal owing to impaired angiogenesis, placental insufficiency and severe atrioventricular septal defects (AVSD) 33, 54 . Although Ccn1 +/-mice are viable, 20% of adult mice display persistent ostium primum atrial septal defects 54 . These defects resemble those observed in patients with mutations in atrioventricular CCN1, cysteine-rich angiogenic inducer 61 (also known as CYR61); CCN2, connective tissue growth factor (also known as CTGF); CCN3, nephroblastoma overexpressed (also known as NOV); CCN4, WNT-inducible signalling pathway protein 1 (also known as WISP1); CCN5, WNT-inducible signalling pathway protein 2 (also known as WISP2); FASL, FAS ligand; HSPG, heparan sulphate proteoglycan; LRP, low-density lipoprotein receptor-related protein; NF-κB, nuclear factor-κB; TNF, tumour necrosis factor; TRKA, neurotrophic tyrosine kinase receptor type 1. *The table shows selected cellular processes that are stimulated (+) or inhibited (-) by CCN proteins in specific cell types, and lists the cell-surface receptors involved.
Atrioventricular septal defects
A form of congenital heart defect in which the heart chambers are poorly formed as a result of impairments in the endocardial cushions, which contribute to the formation of the atrial and ventricular septa, as well as the mitral and tricuspid valves.
Platelet α-granules
Cytoplasmic granules containing many protein factors that are involved in inflammation and wound repair. They are synthesized predominantly in mega karyocytes and include cell-adhesive proteins, growth and coagulation factors, and protease inhibitors, which are released following platelet activation at sites of vessel injury.
septal defect 1 (AVSD1), a susceptibility locus for nonsyndromic AVSD identified by linkage analysis 55 . As the human CCN1 gene and AVSD1 map to the same chromosomal location, these findings suggest that CCN1 may be a candidate gene for AVSD in humans 37 . Ccn2-null mice are perinatal lethal owing to respiratory defects that occur as a secondary consequence of severe skeletal malformations 56 ; observations from these mice are consistent with a wealth of data showing the roles of CCN2 in chondrogenesis and endochondral ossification 38 . Ccn2-null embryos also exhibit pulmonary hypoplasia 57 and decreased numbers of β-cells in the pancreas 58 . Cell-specific deletion of Ccn2 in the ovary and uterus of mice resulted in disrupted follicle development and steroidogenesis, decreased ovulation and increased numbers of corpus lutea 59 . By contrast, Ccn3-knockout mice are viable and largely normal, exhibiting only modest and transient sexually dimorphic skeletal abnormalities 60 . Although Ccn5-null mice suffer early embryonic death 61 , Ccn6-knockout mice display no observable phenotype 62 .
CCN proteins in diseases and targeting studies
As CCN proteins are highly expressed and have important roles at sites of inflammation and tissue repair, they are often deregulated when these processes become chronic and progress to pathological conditions. For this reason, numerous gene profiling studies have found that CCN proteins are aberrantly expressed in a plethora of diseases, many of which are associated with chronic inflammation and tissue repair. Studies in animal models have established that deregulated CCN proteins indeed contribute to the pathologies of many of these diseases, although their mechanisms of action are not completely understood (TABLE 3) . Nevertheless, proof-of-principle studies have shown that targeting CCN proteins can yield substantial benefits in animal models. Moreover, the levels of CCN proteins in biological fluids may serve as non-invasive diagnostic or prognostic biomarkers for certain pathologies. Clinical trials targeting CCN2 are already underway, and initial results are encouraging; as discussed below, these results reinforce the notion that CCN proteins are emerging as attractive therapeutic targets for a broad spectrum of diseases.
Wound healing and fibrotic diseases. Mammalian wound healing and tissue repair occur in a similar way in virtually all organ systems, in three distinct but overlapping phases: first, inflammation occurs, which is followed by the formation of granulation tissue and ECM deposition, and concludes with matrix remodelling and resolution of the granulation tissue 63 . At the site of injury, activated resident fibroblasts and recruited fibrocytes differentiate into αSMA-positive myofibroblasts, which proliferate and deposit ECM proteins to promote healing and support tissue integrity while the damaged tissue is being repaired and remodelled. However, excessive ECM deposition may occur in wound repair, which can lead to fibrosis, scarring and loss of tissue function.
Fibrosis is substantially exacerbated when inflammation or tissue injury becomes chronic, and it contributes to the pathologies of chronic diseases in many organ systems 63, 64 , including the liver (as a result of viral infections or alcoholism), the kidneys (as a result of diabetes) and the heart (as a result of tissue remodelling following myocardial infarction). These pathologies can lead to organ failure and death, yet there is currently no US Food and Drug Administration-approved drug available for treating fibrosis. Emerging studies indicate that various CCN proteins are involved in promoting or inhibiting fibrosis in association with tissue repair, and provide unique opportunities for the development of novel therapeutics and diagnostics for this pathology.
Following wound formation, platelet α-granules release abundant amounts of CCN2 (REFS 65, 66) and other growth factors that can induce the expression of CCN proteins at the site of injury. CCN2 acts synergistically with TGFβ1, a potent pro-fibrotic regulator, to promote matrix protein deposition and fibrogenesis both in vitro and in vivo 67 . Subcutaneous or intraperitoneal injections of either TGFβ or CCN2 individually do not induce persistent fibrosis, whereas co-injection of both proteins together results in sustained fibrosis 68 . CCN2 is overexpressed in human fibrotic diseases of virtually every organ or tissue. Correspondingly, levels of CCN2 in the serum and biological fluids of patients correlate with the severity of systemic fibrosis (known as scleroderma) as well as fibrosis of the heart, kidneys, liver and lungs, which suggests that CCN2 levels in biological fluids may be useful as a non-invasive biomarker for many fibrotic diseases 69, 70 . However, despite this close association with fibrosis, overexpression of Ccn2 in parenchymal cells of most organs does not induce fibrosis in mice but the fibrotic response is exacerbated when these mice are challenged with injury 67 . However, overexpression of Ccn2 specifically in fibroblasts -the major cell type responsible for matrix deposition -is sufficient to drive fibrosis in lung, skin and kidney tissues, as well as arteries 71 . Furthermore, Ccn2 deletion in fibroblasts of mice confers resistance to bleomycin-induced skin fibrosis 72 . These observations suggest that the action of CCN2 in fibroblasts may be strongly autocrine. Consistent with its pro-fibrotic function, inhibition or downregulation of CCN2 ameliorates fibrosis in many organ systems. Knockdown of Ccn2 by antisense oligonucleotides or small interfering RNAs (siRNAs) reduces carbon tetrachloride-induced 73, 74 and N-nitrosodimethylamineinduced 75 liver fibrosis, ureteral obstruction-induced renal fibrosis 76 , fibrotic scarring in cutaneous wounds 77 and renal interstitial fibrogenesis following partial nephrectomy 78 . Although less is known about the functions of CCN4, it has been shown that CCN4 is upregulated in patients with idiopathic pulmonary fibrosis, as well as in a mouse model of bleomycin-induced lung fibrosis; in addition, recombinant CCN4 enhances ECM deposition in human fibroblasts 79 . Correspondingly, orotracheal application of CCN4-neutralizing antibodies to the lung ameliorates bleomycin-induced lung fibrosis in mice 79 . In contrast to the pro-fibrotic activity of CCN2 and CCN4, CCN1 functions to limit fibrosis through a novel mechanism that invokes the induction of cellular senescence in myofibroblasts 8 . Accumulation of senescent cells is an integral part of the normal wound healing response that functions to curb fibrosis, and this process is controlled by CCN1 (REF. 30) (FIG. 4) . CCN1 gradually accumulates in granulation tissue in excisional cutaneous wounds, reaching a level sufficient to trigger senescence in myofibroblasts as the healing process enters the resolution phase, at which point senescent cells express the senescence-associated secretory phenotype that involves the secretion of MMPs and the downregulation of collagen I and TGFβ1 (REF. 8 ). Thus, CCN1 acts as an antifibrotic senescence switch, converting the ECM-synthesizing myofibroblasts into ECM-degrading senescent cells.
This mechanism of controlling fibrosis achieves molecular parsimony by simultaneously halting further ECM production in myofibroblasts, accelerating ECM degradation and facilitating granulation tissue resolution as senescent cells are cleared by natural killer cells 30, 80 . In knock-in mice expressing senescencedefective CCN1, senescent cells do not accumulate in the granulation tissue, and wound healing proceeds with exacerbated fibrosis 8 . Topical treatment of these wounds with purified CCN1 reverses this defect and reduces fibrosis by increasing the number of senescent cells, suggesting a therapeutic potential for CCN1 in the treatment of fibrosis. Interestingly, hepatic stellate cells also undergo senescence to limit fibrosis in a mouse model of chemically induced liver injury 80 , indicating that this mechanism of controlling fibrosis may be a general feature of wound repair in different organs and diverse modes of injuries. Ccn2 (high to low expression)
• Ninefold overexpression of CCN2 causes embryonic death at embryonic day 10 to day 12 • Mice expressing 30% of normal level of CCN2 are viable and normal -201 CCN1, cysteine-rich angiogenic inducer 61 (also known as CYR61); CCN2, connective tissue growth factor (also known as CTGF); CCN3, nephroblastoma overexpressed (also known as NOV); CCN5, WNT-inducible signalling pathway protein 2 (also known as WISP2); CCN6, WNT-inducible signalling pathway protein 3 (also known as WISP3); FASL, FAS ligand; HSPG, heparan sulphate proteoglycan; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor. *Homozygous mice in which both Ccn1 genomic loci have been replaced by the Ccn1-dm allele, which encodes a CCN1 protein that is unable to bind α6β1 integrin-HSPG. ‡ Homozygous mice in which both Ccn2 genomic loci are flanked by the LoxP sequence of bacteriophage P1, allowing specific deletion of the Ccn2 gene in the presence of the Cre recombinase, which is usually expressed under the control of a cell-specific or conditionally activated promoter.
Epithelial-to-mesenchymal transition
A process -typically involving repression of E-cadherin expression -in which epithelial cells lose their adhesive properties and gain mobility. This transition is essential for many developmental processes and occurs during oncogenic transformation.
Although CCN1 inhibits fibrosis by inducing cellular senescence 8 , CCN3 and CCN5 appear to exert antifibrotic activities through alternative mechanisms. CCN3 suppresses CCN2 and collagen I expression in mesangial cells in vitro 81 , whereas overexpression of CCN5 reduces cardiac hypertrophy and fibrosis in transgenic mice, possibly by inhibiting TGFβ-SMAD signalling 82 . As CCN2 and CCN4 are pro-fibrotic (and CCN1, CCN3 and CCN5 are antifibrotic, at least in certain biological contexts), it is crucial that reagents that target members of the CCN protein family have a high level of specificity. Approaches in this regard are discussed below.
CCN proteins in cancer.
It has long been recognized that chronic injuries and deregulated wound healing are risk factors in the development of cancer 83 . Recent studies have further underscored the important role of inflammation in tumorigenesis and tumour progression 84 . Inflammation occurring at early stages of neoplastic transformation can accelerate the development of incipient neoplasias into full-blown cancer by releasing mutagenic chemicals such as reactive oxygen species. Moreover, inflammation is associated with most -if not all -tumours, and contributes to cancer progression by providing a rich arsenal of biologically active molecules to the tumour microenvironment, including factors that promote cell growth, survival, motility, invasion, angiogenesis and matrix degradation. Aberrant expression of CCN proteins has been identified in a range of tumour types 85 . With some notable exceptions 86, 87 CCN1, CCN2 and CCN4 have generally been associated with the promotion of cell proliferation and tumour growth, whereas CCN3, CCN5 and CCN6 have been associated with inhibition of these processes (TABLE 4) .
CCN1 and CCN2 may enhance tumour growth through their potent angiogenic activity 31, 88 . Accordingly, forced expression of CCN1 in breast cancer cells promotes tumour growth in xenografts with increased vascularization 89, 90 , and expression of CCN2 in tumourreactive stroma enhances the density of microvessels in xenograft tumours in nude mice 91, 92 . Consequently, xenograft tumour growth is inhibited by silencing the expression of either CCN1 or CCN2 in cancer cells of the prostate 93 , pancreas 94, 95 and ovary 96 . Both CCN1 and CCN2 can promote epithelial-to-mesenchymal transition 95, 97 , enhance the survival of some cancer cells through the induction of anti-apoptotic proteins 98, 99 and mediate resistance to paclitaxel in breast cancer 100 . Direct intratumoural delivery of CCN1 siRNA into pre-established glioma xenografts decreases tumour growth by up to 40% in a dose-dependent manner, suggesting that targeting CCN1 has therapeutic potential 101 . Furthermore, CCN2 is a key component of the gene signature that facilitates metastasis to bone 102 , and treatment of nude mice with a CCN2-specific murine monoclonal antibody markedly decreased osteolytic bone metastasis of human breast cancer cell xenografts 103 . Notably, administration of FG-3019, a CCN2-specific humanized monoclonal antibody, inhibits tumour growth and metastases in xenograft and orthotopic mouse models of pancreatic cancer 104, 105 . As human pancreatic cancers are largely recalcitrant to therapy, the possibility of treating this form of cancer by targeting CCN2 is particularly encouraging.
Overexpression of CCN4 in normal rat kidney fibroblasts confers the ability to form tumours in nude mice 106 , and elevated CCN4 expression has been observed in advanced breast and colon cancers 107, 108 as well as adenosquamous lung carcinomas 109 . However, CCN4 appears to inhibit metastasis and is preferentially expressed in melanoma cell lines with a low metastastic potential 110 . Lung cancer cells overexpressing CCN4 are less invasive and exhibit reduced metastasis in nude mice, possibly owing to the integrin-mediated inhibition of RAC by CCN4 (REF. 111) . A splice variant of CCN4 lacking the VWC domain has been detected in scirrhous gastric carcinomas, and transfectants expressing this variant enhance the invasive characteristic of co-cultured gastric carcinoma cells 112 . Therefore, it is possible that CCN4 isoforms expressed as a result of differential splicing might underlie the pro-and anti-invasive activities of CCN4, although this possibility has not been thoroughly investigated.
CCN3, CCN5 and CCN6 have a negative effect on cell proliferation. Although CCN3 inhibits the proliferation of cancer cells 113 , it appears to promote metastasis 20 . Overexpression of CCN3 results in reduced tumour size in glioma cell xenografts 114 but enhances metastatic potential in xenotransplanted melanoma cells 115 . CCN3 expression is associated with a higher risk of metastasis and worse prognosis in patients with cancers such as Ewing's sarcoma 116 , melanoma 115 and breast cancer 117 . In addition to solid tumours, CCN3 is downregulated in chronic myeloid leukaemia as a consequence of the activity of breakpoint cluster region (BCR)-ABL kinase, a chimeric protein generated through the chromosomal translocation between chromosome 9 and chromosome 22 (REF. 118 ). CCN3 expression is increased in patients who respond to imatinib therapy. Forced expression of CCN3 inhibits proliferation and restores growth control in chronic myeloid leukaemia cells, and sensitizes them to imatinib-induced apoptosis, suggesting that CCN3 may be an alternative target for novel therapeutics against chronic myeloid leukaemia 119 . CCN5 inhibits the growth of vascular smooth muscle cells, uterine myometrial cells, leiomyoma cells and oestrogen receptor-negative breast cancer cells 61 . CCN5 expression is significantly decreased in leiomyomas, pancreatic cancers and salivary gland tumours. CCN6 is expressed in the normal mammary epithelium but its expression is lost or downregulated in 60% of inflammatory breast carcinomas, and restoration of CCN6 expression reduces tumour growth in nude mice 120 . It has been suggested that CCN6 acts by interfering with the insulin-like growth factor 1 signalling pathway, which promotes the proliferation, survival and meta stasis of breast cancer cells 121 . CCN proteins can therefore act both positively and negatively in tumorigenesis and tumour progression, depending on the tumour type. Although CCN1 and CCN2 are known inducers of angiogenesis, and may promote the growth of some tumour types, they can also suppress tumour growth in some cancers 86, 87 . CCN1, CCN2 and CCN3 can synergize with cytokines of the TNF family -particularly TNF-related apoptosisinducing ligand, which preferentially kills tumour cells 27 -to induce apoptosis, and CCN1 can induce cellular senescence 8 . Both apoptosis and senescence are wellestablished mechanisms of tumour suppression if they are triggered in damaged cells that are at risk of neoplastic transformation 122 , which suggests that CCN proteins may inhibit the development of incipient tumours by promoting apoptosis or senescence in damaged cells.
It is important to note that most experimental studies on the functions of CCN proteins in cancer have used xenograft models and established tumour cell lines, and thus focus on tumour growth and progression rather than the initial stages of tumorigenesis. Whether CCN proteins exert a positive or negative effect on tumour growth may depend on the type of integrin that is preferentially expressed on the tumour cells (for example, αVβ3 integrin is growth-promoting, whereas α6β1 integrin is growth-inhibitory when CCN1 is used as a ligand) 37 . In addition, the positive or negative effect of CCN proteins on tumour growth depends on whether angiogenic factors are limiting, and whether conditions that favour apoptosis or senescence (that is, the accumulation of reactive oxygen species) prevail. Despite these uncertainties regarding how CCN proteins function in tumorigenesis, targeting CCN proteins has shown therapeutic promise in specific cancers (as described above), and these approaches warrant further translational studies.
Diabetic nephropathy and retinopathy. Diabetes is associated with a multitude of metabolic and homeostatic abnormalities, including hyperglycaemia as well as systemic and intraglomerular hypertension, which contribute to microvascular pathologies such as diabetic nephropathy and retinopathy. Substantial evidence from recent studies supports the involvement of chronic inflammation in the pathogenesis of diabetic nephropathy and retinopathy 123, 124 . Chronic hyperglycaemia -the hallmark of diabetes -is a pro-inflammatory condition that leads to multiple biochemical alterations including the formation of advanced glycation end products, which are thought to trigger or amplify many aspects of diabetes pathology 125 . Exposure to high levels of glucose stimulates CCN2 expression in human mesangial cells 126 , and the expression of both CCN1 and CCN2 is induced by advanced glycation end products in vitro and in vivo 127, 128 . In addition, mechanical stretch and haemodynamic forces simulating hypertension induce the expression of CCN1 and CCN2 in vascular endothelial cells and smooth muscle cells, and the expression of CCN2 in renal mesangial cells 129 . Thus, hyperglycaemia and hypertension are both factors that contribute to the progression of diabetic disease that is associated with the induction of CCN1 and CCN2 expression.
Diabetic nephropathy is characterized by hypertrophy of glomeruli and tubules, thickening of their associated basement membrane, and glomerular and interstitial fibrosis; all of these factors compromise kidney function 130 . Microalbuminuria at the incipient stage of diabetic nephropathy progresses to overt proteinuria as glomerular filtration deteriorates. In patients with diabetes, CCN2 expression is increased in both glomerular podocytes and mesangial cells 130 , whereas CCN1 expression in podocytes is downregulated 131 . CCN2 induces pro-fibrotic responses in cultured human mesangial cells and promotes the infiltration of inflammatory cells into the renal interstitium 130, 132 . Treatment of diabetic rats with aminoguanidine to inhibit the formation of advanced glycation end products concomitantly blocks the induction of Ccn2 expression and albuminuria 127 . Knockdown of Ccn2 expression by antisense oligonucleotides attenuates the progression of nephropathy in mouse models of diabetes 133 , whereas transgenic overexpression of CCN2 in podocytes enhances urinary albuminuria 134 . Current methods of treating diabetic nephropathy focus on the control of renal hypertension using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers 135 ; targeting CCN2 may therefore provide an alternative or complementary form of therapy. Moreover, plasma and urinary levels of CCN2 in patients with diabetes correlate with clinical parameters associated with the severity of diabetic nephropathy, suggesting that CCN2 can be a useful biomarker for this disease 136, 137 . Cysteine-rich angiogenic inducer 61 (CYR61; also known as CCN1) and connective tissue growth factor (CTGF; also known as CCN2) have distinct roles in wound healing. CCN2 functions in the granulation tissue during the proliferative phase and interacts with transforming growth factor-β (TGFβ) to promote the synthesis of the extracellular matrix (ECM), leading to a pro-fibrotic response. As wound healing progresses, CCN1 accumulates to a sufficiently high level to induce an antifibrotic senescence switch in myofibroblasts, thereby limiting fibrosis by converting the ECM-synthesizing myofibroblasts into ECM-degrading senescent cells. MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase.
Retinopathy is a common microvascular complication of diabetes, which is caused by enhanced angiogenesis and fibrosis in the vitreous cavity of the eye, and results in loss of vision. CCN1 appears to be involved in retinal angio genesis in rodent models of streptozotocininduced diabetes or oxygen-induced retinopathy, and in proliferative diabetic retinopathy in humans 128, 138 . Intravitreal injection of a neutralizing CCN1-specific antibody in the oxygen-induced retinopathy mouse model significantly reduces retinal neovascularization with no apparent toxicity or inflammation 138 . CCN2 is highly expressed in microvascular pericytes of the human diabetic retina, and ALL, acute lymphoblastic leukaemia; CCN1, cysteine-rich angiogenic inducer 61 (also known as CYR61); CCN2, connective tissue growth factor (also known as CTGF); CCN3, nephroblastoma overexpressed (also known as NOV); CCN4, WNT-inducible signalling pathway protein 1 (also known as WISP1); CCN5, WNT-inducible signalling pathway protein 2 (also known as WISP2); CCN6, WNT-inducible signalling pathway protein 3 (also known as WISP3); CML, chronic myloid leukaemia; p53, cellular tumour antigen p53.
its levels correlate with the degree of fibrosis in vitreoretinal disorders 139 . Heterozygous Ccn2 +/− mice subjected to streptozotocin-induced diabetes exhibit significantly lower basal membrane thickening of retinal capillaries than wild-type mice 140 . These results are consistent with the notion that targeting CCN proteins may help to amelio rate the pathology of diabetic retinopathy. Cardiovascular diseases. CCN proteins have been implicated in several vascular pathologies, including atherosclerosis, restenosis, thrombosis and hypertension. Atherosclerosis is a chronic inflammatory disease of the arterial wall that is triggered by the prolonged elevation of lipids in the bloodstream (known as hyperlipidaemia), whereas proliferative restenosis is a common response to vascular injury after balloon angioplasty. CCN1 and CCN2 promote neointimal hyperplasia after vascular injury, whereas CCN3 and CCN5 inhibit it. High levels of both CCN1 and CCN2 have been detected in ruptureprone atherosclerotic plaques -particularly in areas of neovascularization or in areas that are infiltrated with inflammatory cells 141, 142 -as well as in the neointima in restenosis after balloon injuries in rats 22, 143 . Inhibiting Ccn1 expression using either its negative regulator forkhead box protein O3A 144 or siRNA 145 effectively reduced neointimal hyperplasia following balloon injury in a rat carotid artery. As neointimal hyperplasia is a common complication in the treatment of atherosclerosis, targeting CCN1 may be beneficial. By contrast, Ccn3 expression is substantially reduced following balloon injury. CCN3 inhibits smooth muscle cell proliferation in culture, and Ccn3-null mice suffer from enhanced neointimal thickening when challenged with vascular injury, which indicates that CCN3 inhibits neointimal hyperplasia 24 . Likewise, CCN5 inhibits vascular smooth muscle cell proliferation and motility, and its expression is substantially reduced in arteries after balloon-induced injury 23 . CCN1 is upregulated in inflammatory cardiomyopathy in humans, and CCN1 gene transfer in animal models attenuates autoimmune myocarditis by inhibiting the infiltration of spleen macrophages and lymphocytes into the myocardium 47 . The effects of CCN1 on immune cells are partially mimicked by cyclic RGD peptides, which bind to αV integrins and are in clinical trials as cancer therapeutics 146 . Both CCN1 and CCN2 are substantially upregulated in cardiomyocytes of patients with ischaemic cardiomyopathy, and during cardiac remodelling after myocardial infarction 147, 148 . Cardiomyocyte-specific expression of CCN2 alone in transgenic mice did not induce fibrosis but it did exacerbate pressure overloadinduced cardiac fibrosis 82 and led to cardiomyocyte hypertrophy by the time the mice were 7 months old 149 . By contrast, CCN5 inhibits the CCN2-induced hypertrophic responses in cardiomyocytes, and transgenic expression of CCN5 in cardiomyocytes reduces pressure overload-induced cardiac fibrosis 82 . These results indicate that CCN2 and CCN5 have opposing roles in cardiac hypertrophy and fibrosis. CCN5 is the only member of the CCN protein family that lacks the C-terminal domain. Deleting the C-terminal domain of CCN2 renders it CCN5-like in inhibiting hypertrophic responses in cardiomyocytes in vitro, and fusing the C-terminal domain of CCN2 to CCN5 transforms the latter protein into a CCN2-like pro-hypertrophic molecule 82 ; this indicates that the C-terminal domain of CCN2 has a pro-fibrotic function.
Arthritis and other inflammatory diseases. Osteoarthritis is a common and debilitating degenerative disease affecting the joints, for which the principal forms of treatment provide only temporary pain management, and surgery may be required if joint degeneration is severe. Both CCN2 and CCN4 are strongly upregulated in the cartilage of patients with osteoarthritis 150, 151 . CCN4 contributes to cartilage damage by inducing the production of MMPs and aggrecanase in macrophages and chondrocytes 151 . CCN2 promotes the proliferation and differentiation of chondrocytes without inducing calcification of articular cartilage 38 . Direct injection of CCN2 into the joint cavity stimulates cartilage repair in a rat model of osteoarthritis, which suggests that CCN2 may have therapeutic potential in treating osteoarthritis 152 . CCN1 and CCN2 are highly expressed in hypertrophic and proliferative chondrocytes during fracture healing, and blockade of CCN1 function by neutralizing antibodies inhibits bone fracture healing in mice 153, 154 . CCN1 and CCN2 are both highly expressed in rheumatoid arthritis, which is an inflammatory joint disorder that leads to the destruction of articular cartilage 155, 156 . CCN1 may contribute to hyperplasia of the synovial lining, resulting in joint destruction in rheumatoid arthritis. CCN2 synergizes with macrophage colonystimulating factor and receptor activator of NF-κB ligand to enhance osteoclastogenesis, and contributes to bone destruction in the disorder 155 . Current therapies for recalcitrant rheumatoid arthritis include monoclonal antibodies (such as infliximab, golimumab, adalimumab and certolizumab pegol) that target TNF, which can regulate the expression of the CCN gene family and functionally interact with CCN proteins 7, 36 . In this regard, it is interesting to note that TNF antagonists are also effective therapies in inflammatory bowel disease, and CCN1 is upregulated 10-20-fold in patients with Crohn's disease or ulcerative colitis 157 , suggesting that CCN1 and TNF may functionally interact in these diseases as well.
In the central nervous system, chronic inflammationlike responses of glial cells cause neurodegenerative events including plaque formation, dystrophic neurite growth and excessive phosphorylation of the microtubuleassociated protein tau. Thus, neuroinflammation has been implicated in several pathological conditions affecting the central nervous system, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis. Elevated CCN2 expression is observed in brain neurons and astrocytes from patients with Alzheimer's disease, and its expression levels correlate with the progression of clinical dementia and the deposition of neuritic plaques and neurofibrillary tangles 158 . Moreover, CCN2 promotes the processing of amyloid precursor protein and the subsequent generation of amyloid-β peptide in vitro 159 , which suggests that CCN2 may contribute to the progression of astrocytes by enhancing β-amyloidosis. However, the normal functions of CCN proteins in the central nervous system are currently unclear.
Genetic mutations and polymorphisms in human diseases. Out of the six members of the CCN gene family, only CCN6 has been associated with a human disease that has Mendelian inheritance. Mutations in CCN6 cause the autosomal recessive skeletal disease progressive pseudorheumatoid dysplasia, a juvenile-onset degenerative disease of the joints 160 . Alleles that cause progressive pseudorheumatoid dysplasia harbour loss-of-function mutations including deletions as well as frameshift, nonsense and missense mutations 160 . The development of DNA-based prenatal diagnosis strategies to target CCN6 may be useful for identifying families who are at risk of developing progressive pseudorheumatoid dysplasia, as symptoms of this disease are seen from 3 to 8 years of age. Genetic disruption of Ccn6 in mice fails to recapitulate the human disease and presents no discernible phenotype 62 , although in zebrafish ccn6 modulates the canonical BMP and WNT signalling pathways that are crucial for cartilage homeostasis 161 .
Polymorphisms have been identified in the DNA sequence of genes encoding CCN proteins that are associated with various diseases (TABLE 5) . Notably, polymorphisms in the human CCN2 gene have been found to be significantly associated with scleroderma [162] [163] [164] , although some of these results may be controversial 165 . Other poly morphisms in the CCN gene family have been associated with susceptibility to hypertension, type 1 diabetes, colorectal cancer, hepatic fibrosis and so on. How these polymorphisms affect the expression or function of genes encoding CCN proteins is largely unknown and warrants further studies.
Therapeutic approaches and clinical trials
Much of the clinical potential of therapeutically targeting CCN proteins is still largely unexplored, as translational studies are still in early stages. As CCN proteins are secreted, humanized monoclonal antibodies are particularly well suited as blocking agents for their activities and thus hold promise as potential therapeutics. In this regard, the hinge region of the protein -which is encoded by the same exon as the VWC domain
-may be a good choice of antigen, as this region is unique to each member of the CCN protein family and contains an abundance of charged amino acids, thus enhancing its antigenicity. Other targeting strategies, such as the use of siRNA or antisense oligonucleotides to downregulate the expression of genes encoding specific CCN proteins, have been successful in animal models 166 . These approaches can also afford a high degree of target gene specificity if possible off-target effects are minimized through careful selection of oligonucleotide sequences.
The use of synthetic peptides as targeting agents for CCN proteins has not been explored in as much detail but nevertheless has some therapeutic potential. For example, recent studies show that decorin can bind CCN2 directly through its leucine-rich repeat domain and inhibit the pro-fibrotic activity of CCN2 (REF. 167 ), suggesting the possibility of targeting CCN2 using a binding peptide. However, decorin is also known to bind other members of the CCN protein family and may not interact specifically with CCN2 (REF. 168 ). As CCN proteins interact with αVβ3 integrins to mediate angiogenic functions 31, 169 , peptides that bind αVβ3 integrin and inhibit αVβ3 integrin-mediated signalling may thwart CCN1-promoted angiogenesis in tumour growth. However, this strategy -targeting αVβ3 integrin -is not specific to CCN proteins. Other peptides have been identified that block the binding of CCN proteins to α6β1 integrin and HSPGs, and inhibit activities mediated through these receptors 170, 171 , although the utility of these peptides in blocking the functions of CCN proteins has not been investigated in vivo.
Several clinical trials targeting CCN2 have either been carried out or are underway. A Phase I study to evaluate the safety and tolerability of FG-3019 (REF. 172 ) was performed in patients with mild to moderate idiopathic pulmonary fibrosis; results showed that the humanized antibody was safe and well tolerated 173 . A follow-up Phase II study is currently underway (ClinicalTrials. gov identifier: NCT01262001). Another Phase Ib study showed that FG-3019 was well tolerated in the treatment of patients with type 1 or type 2 diabetes and microalbuminuria 6 . The observation that the urinary albumin/ creatinine ratio was reduced by more than 50% by the end of the treatment is particularly encouraging as it suggests that the blockade of CCN2 is associated with a decrease in albuminuria.
A similar Phase I study has also been completed in patients with type 1 or type 2 diabetes who had a more severe form of microalbuminuria and were receiving background treatment for hypertension (ClinicalTrials. gov identifier: NCT00754143). On the strength of these observations, a Phase II study was initiated in patients with type 2 diabetes and advanced kidney disease to evaluate the effect of FG-3019 on renal function and associated cardiovascular comorbidities (ClinicalTrials. gov identifier: NCT00913393). Another ongoing Phase I study is evaluating FG-3019 therapy in combination with gemcitabine (a nucleoside analogue chemotherapeutic drug) and erlotinib (a tyrosine kinase inhibitor) for patients with locally advanced or metastatic pancreatic cancer (ClinicalTrials.gov identifier: NCT01181245). In addition, a Phase II study has been initiated in patients with liver fibrosis caused by chronic hepatitis B infection in which the efficacy of FG-3019 for reversing fibrosis is being evaluated (ClinicalTrials.gov identifier: NCT01217632).
Aside from monoclonal antibodies, a 2-O-methoxyethyl-modified antisense oligonucleotide (EXC-001) designed to inhibit CCN2 expression has been used in several Phase II clinical trials to study its effects in controlling scarring after breast surgery (ClinicalTrials. gov identifier: NCT01037413) or abdominoplasty surgery (ClinicalTrials.gov identifiers: NCT01037985; NCT01038297). Results show a reduction in scarring with no significant drug-related adverse effects (see the 10 January 2011 press release on the Excaliard Pharmaceuticals website). In addition, RXI-109, a selfdelivering RNA interference compound that reduces CCN2 expression, is due to enter clinical trials (see the 7 September 2011 press release on the Galena Biopharma website). It is encouraging that no side effects have been observed in Phase I trials involving humanized monoclonal antibodies or antisense oligonucleotides targeting CCN2. As CCN proteins are generally downregulated in many tissues in adulthood and are highly expressed only at sites of inflammation and tissue repair, it is likely that therapeutic targeting of CCN proteins will preferentially affect the sites of pathology and have minimal impact on the normal functions of organs and tissues. Pregnancy might be an exception, as systemic targeting of certain CCN proteins may increase the risk of pre-eclampsia 174 or inhibit placentation 33 .
Conclusions and future directions
The CCN matricellular proteins have important roles in modulating inflammation and tissue repair, and they are often deregulated in a broad spectrum of pathologies that develop when these processes become chronic. Emerging studies have identified opportunities in which levels of CCN proteins in biological fluids may serve as non-invasive diagnostic or prognostic tools -for example, systemic fibrosis 69, 175 , diabetic nephropathy 137 and renal hypertension 136 , as well as some forms of cancer 87, 116, 176 . The potential of monitoring CCN proteins for the non-invasive assessment of fibrosis is of particular clinical interest. Studies in various animal models have also demonstrated that targeting relevant genes encoding CCN proteins in several diseases -such as cancer, diabetic nephropathy and fibrosis of the liver, kidney and skin -could be therapeutically beneficial. Clinical trials targeting CCN2 have been initiated, and preliminary results are encouraging. We surmise that as studies on CCN proteins progress, more pathologies will be identified for which CCN proteins could serve as potential diagnostic or therapeutic targets.
Among the key challenges in future research is the ability to elucidate the specific role of CCN proteins in disease aetiology. In only a few cases has there been limited functional insight into how CCN proteins might be triggering or contributing to disease pathology. Understanding the crucial pathological role of CCN proteins and their mechanisms of action will help to identify relevant targets for therapeutic intervention as the key signalling steps in these processes are identified. As some members of the CCN protein family often have opposing roles, the expression of a specific CCN protein may be either deleterious or beneficial in a particular pathological context. Therefore, the specificity of reagents targeting members of the CCN protein family is of paramount importance. Furthermore, it is currently unclear how various CCN proteins interact to provoke antithetical effects in some contexts. Future studies that clarify how CCN proteins with opposing functions operate mechanistically could present further prospects for combinatorial therapies that simultaneously downregulate and upregulate the expression or function of rival members of the CCN protein family, thus potentially magnifying the therapeutic impact.
Although CCN proteins represent unusual opportunities as therapeutic targets in a broad spectrum of diseases (as discussed above), their therapeutic potential has so far remained relatively underexplored. Clinical trials that are currently being carried out and planned are investigating the efficacy of targeting only CCN2; other members of the CCN protein family have not yet been investigated, despite having apparent roles in many of the same pathologies as CCN2. This may be due in part to the lack of coordinated efforts to develop humanized neutralizing monoclonal antibodies targeting other members of the CCN protein family, although studies using other targeting strategies can be initiated. As the relative efficacies of targeting distinct members of the CCN protein family in the same pathologies remain to be determined, future studies that investigate the full range of CCN proteins as therapeutic targets will be of considerable interest. CCN1, cysteine-rich angiogenic inducer 61 (also known as CYR61); CCN2, connective tissue growth factor (also known as CTGF); CCN3, nephroblastoma overexpressed (also known as NOV); CCN4, WNT-inducible signalling pathway protein 1 (also known as WISP1); CCN5, WNT-inducible signalling pathway protein 2 (also known as WISP2); CCN6, WNT-inducible signalling pathway protein 3 (also known as WISP3); HDL, high-density lipoprotein; ND, not determined; rs, reference SNP ID number; SNP, single nucleotide polymorphism.
